Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage

Molecular Oncology

Volumn 9, Issue 2, 2015, Pages 409-421

  Xie, Chengzhi ^a,b   Edwards, Holly ^a   Caldwell, J Timothy ^a   Wang, Guan ^a,b   Taub, Jeffrey W ^a,c   Ge, Yubin ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; DNA damage; Drug combination; Obatoclax

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CASPASE 3; CASPASE 9; CYTARABINE; DAUNORUBICIN; DOUBLE STRANDED DNA; HISTONE H2AX; OBATOCLAX; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; VENETOCLAX; ANTINEOPLASTIC ANTIMETABOLITE; PYRROLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IC50; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; MTT ASSAY; PRIORITY JOURNAL; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; U937 CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CYTARABINE; DNA DAMAGE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PYRROLES; U937 CELLS;

EID: 84921290853     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.09.008     Document Type: Article

References (58)

1. Bonneau B., Prudent J., Popgeorgiev N., Gillet G. Non-apoptotic roles of Bcl-2 family: the calcium connection. Biochim. Biophys. Acta 2013, 1833:1755-1765.
2. Bose P., Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk. Res. Rep. 2013, 2:12-14.
3. Caldwell J.T., Edwards H., Dombkowski A.A., Buck S.A., Matherly L.H., Ge Y., Taub J.W. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia. PloS One 2013, 8:e68601.
4. Choi B.H., Chakraborty G., Baek K., Yoon H.S. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp. Mol. Med. 2013, 45:e47.
5. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
6. Cuconati A., Mukherjee C., Perez D., White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003, 17:2922-2932.
7. Dutta C., Day T., Kopp N., van Bodegom D., Davids M.S., Ryan J., Bird L., Kommajosyula N., Weigert O., Yoda A., Fung H., Brown J.R., Shapiro G.I., Letai A., Weinstock D.M. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012, 72:4193-4203.
8. Edwards H., Xie C., LaFiura K.M., Dombkowski A.A., Buck S.A., Boerner J.L., Taub J.W., Matherly L.H., Ge Y. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009, 114:2744-2752.
9. Fennell D.A., Corbo M.V., Dean N.M., Monia B.P., Cotter F.E. Invivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model. Br. J. Haematol. 2001, 112:706-713.
10. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
11. Ge Y., Dombkowski A.A., LaFiura K.M., Tatman D., Yedidi R.S., Stout M.L., Buck S.A., Massey G., Becton D.L., Weinstein H.J., Ravindranath Y., Matherly L.H., Taub J.W. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006, 107:1570-1581.
12. Ge Y., Stout M.L., Tatman D.A., Jensen T.L., Buck S., Thomas R.L., Ravindranath Y., Matherly L.H., Taub J.W. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J.Natl. Cancer Inst. 2005, 97:226-231.
13. Goard C.A., Schimmer A.D. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid. 2013, 8:15-26.
14. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
15. Hwang J.J., Kuruvilla J., Mendelson D., Pishvaian M.J., Deeken J.F., Siu L.L., Berger M.S., Viallet J., Marshall J.L. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 2010, 16:4038-4045.
16. Jamil S., Mojtabavi S., Hojabrpour P., Cheah S., Duronio V. An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. Mol. Biol. Cell 2008, 19:3212-3220.
17. Jamil S., Sobouti R., Hojabrpour P., Raj M., Kast J., Duronio V. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. Biochem. J. 2005, 387:659-667.
18. Jamil S., Stoica C., Hackett T.L., Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle 2010, 9:2843-2855.
19. Kaspers G.J., Zwaan C.M. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007, 92:1519-1532.
20. Keith F.J., Bradbury D.A., Zhu Y.M., Russell N.H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995, 9:131-138.
21. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., Bornmann W., Kantarjian H., Viallet J., Samudio I., Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68:3413-3420.
22. Kumar T.S., Kari V., Choudhary B., Nambiar M., Akila T.S., Raghavan S.C. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J.Biol. Chem. 2010, 285:32657-32670.
23. Laulier C., Barascu A., Guirouilh-Barbat J., Pennarun G., Le Chalony C., Chevalier F., Palierne G., Bertrand P., Verbavatz J.M., Lopez B.S. Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res. 2011, 71:3590-3602.
24. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., Forconi F., Tura S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leuk. 1997, 11:2075-2078.
25. Leber B., Geng F., Kale J., Andrews D.W. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev. Mol. Med. 2010, 12:e28.
26. Li J., Viallet J., Haura E.B. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother. Pharmacol. 2008, 61:525-534.
27. Maiuri M.C., Criollo A., Tasdemir E., Vicencio J.M., Tajeddine N., Hickman J.A., Geneste O., Kroemer G. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007, 3:374-376.
28. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8:741-752.
29. Malik S.A., Orhon I., Morselli E., Criollo A., Shen S., Marino G., BenYounes A., Benit P., Rustin P., Maiuri M.C., Kroemer G. BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 2011, 30:3918-3929.
30. Mohammad R.M., Goustin A.S., Aboukameel A., Chen B., Banerjee S., Wang G., Nikolovska-Coleska Z., Wang S., Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res. 2007, 13:2226-2235.
31. Munoz-Gamez J.A., Rodriguez-Vargas J.M., Quiles-Perez R., Aguilar-Quesada R., Martin-Oliva D., de Murcia G., Menissier de Murcia J., Almendros A., Ruiz de Almodovar M., Oliver F.J. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 2009, 5:61-74.
32. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003, 17:1475-1486.
33. Niu X., Wang G., Wang Y., Caldwell J.T., Edwards H., Xie C., Taub J.W., Li C., Lin H., Ge Y. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leuk. 2014, 28:1557-1560.
34. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
35. Pan J., Cheng C., Verstovsek S., Chen Q., Jin Y., Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett. 2010, 293:167-174.
36. Pawlikowska P., Leray I., de Laval B., Guihard S., Kumar R., Rosselli F., Porteu F. ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ. 2010, 17:1739-1750.
37. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
38. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
39. Rubnitz J.E., Inaba H., Dahl G., Ribeiro R.C., Bowman W.P., Taub J., Pounds S., Razzouk B.I., Lacayo N.J., Cao X., Meshinchi S., Degar B., Airewele G., Raimondi S.C., Onciu M., Coustan-Smith E., Downing J.R., Leung W., Pui C.H., Campana D. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010, 11:543-552.
40. Saintigny Y., Dumay A., Lambert S., Lopez B.S. A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 2001, 20:2596-2607.
41. Saxena A., Viswanathan S., Moshynska O., Tandon P., Sankaran K., Sheridan D.P. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am. J. Hematol. 2004, 75:22-33.
42. Schimmer A.D., O'Brien S., Kantarjian H., Brandwein J., Cheson B.D., Minden M.D., Yee K., Ravandi F., Giles F., Schuh A., Gupta V., Andreeff M., Koller C., Chang H., Kamel-Reid S., Berger M., Viallet J., Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:8295-8301.
43. Schmitt E., Beauchemin M., Bertrand R. Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) during G2/M cell-cycle checkpoint. Oncogene 2007, 26:5851-5865.
44. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
45. Suzuki K., Bose P., Leong-Quong R.Y., Fujita D.J., Riabowol K. REAP: a two minute cell fractionation method. BMC Res. Notes 2010, 3:294.
46. Tallarida R.J. Drug synergism: its detection and applications. J.Pharmacol. Exp. Ther. 2001, 298:865-872.
47. Taub J.W., Matherly L.H., Stout M.L., Buck S.A., Gurney J.G., Ravindranath Y. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996, 87:3395-3403.
48. Urtishak K.A., Edwards A.Y., Wang L.S., Hudome A., Robinson B.W., Barrett J.S., Cao K., Cory L., Moore J.S., Bantly A.D., Yu Q.C., Chen I.M., Atlas S.R., Willman C.L., Kundu M., Carroll A.J., Heerema N.A., Devidas M., Hilden J.M., Dreyer Z.E., Hunger S.P., Reaman G.H., Felix C.A. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 2013, 121:2689-2703.
49. Vogler M., Weber K., Dinsdale D., Schmitz I., Schulze-Osthoff K., Dyer M.J., Cohen G.M. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009, 16:1030-1039.
50. Wang J., Beauchemin M., Bertrand R. Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 2012, 11:2159-2169.
51. Wang Q., Gao F., May W.S., Zhang Y., Flagg T., Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell 2008, 29:488-498.
52. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., Hu Y., Tambaro F.P., Viallet J., O'Brien S., Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin. Cancer Res. 2010, 16:3923-3932.
53. Xie C., Drenberg C., Edwards H., Caldwell J.T., Chen W., Inaba H., Xu X., Buck S.A., Taub J.W., Baker S.D., Ge Y. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PloS One 2013, 8:e79106.
54. Xie C., Edwards H., Lograsso S.B., Buck S.A., Matherly L.H., Taub J.W., Ge Y. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr. Blood Cancer 2012, 59:1245-1251.
55. Xie C., Edwards H., Xu X., Zhou H., Buck S.A., Stout M.L., Yu Q., Rubnitz J.E., Matherly L.H., Taub J.W., Ge Y. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin. Cancer Res. 2010, 16:5499-5510.
56. Xu X., Xie C., Edwards H., Zhou H., Buck S.A., Ge Y. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PloS One 2011, 6:e17138.
57. Yu L., Liu S. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics. Semin. Cancer Biol. 2013, 23:553-560.
58. Zhan Q., Bieszczad C.K., Bae I., Fornace A.J., Craig R.W. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene 1997, 14:1031-1039.